We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PUSH FOR MEDICARE RX DIRECT PRICE NEGOTIATION LIKELY TO FAIL IN HOUSE

PUSH FOR MEDICARE RX DIRECT PRICE NEGOTIATION LIKELY TO FAIL IN HOUSE

March 22, 2006

House Democrats' effort to clear the way for HHS to directly negotiate Medicare drug prices will likely fail as the House Rules Committee seems poised to block such a proposal, committee staffers say.

House members are contemplating an effort to get language into the budget resolution giving the federal government the ability to negotiate directly with drug manufacturers for lower Medicare costs. This effort comes on the heels of a victory in the Senate for direct negotiation.

If lawmakers are successful in adding this language to the federal budget, it will lower the procedural bar for such a change to become law. Under parliamentary procedure, if an amendment is not in the budget it can be stopped by a point of order. It takes a 60-vote super majority to overcome a point of order. Defeating a point of order "has been a barrier in the past" for controversial bills, said Jill Greenberg, spokeswoman for Sen. Ron Wyden (D-Ore.).

If the language is included in the budget, only 51 votes will be required. Similar legislation introduced by Wyden and Sen. Olympia Snowe (R-Maine) received 50 votes last March, falling one vote short for passage.

House proponents may attempt to add to the budget resolution a bill, H.R. 752, which would remove the Medicare Rx Law's "noninterference" language - the provision that currently prohibits direct negotiations. Rep. Marion Berry (D-Ark.), sponsor of H.R. 752, and other lawmakers have attempted to add this language to previous legislation, including a recent emergency supplemental funding bill. The congressman is open to any opportunity to pass this legislation, said Berry spokeswoman Lillian Pace.

But this effort will likely fail because of Republican opposition within the Rules Committee, a minority staffer on that committee said. The committee can prevent an amendment from being added to the budget by arguing that a topic is nongermane, and is likely to do so here, the source added.

Republicans oppose inserting direct negotiation language because it would alter the Medicare Rx Law, the source said. Republicans and industry opponents argue government negotiation would result in federal price controls, limiting the ability of market forces to dictate costs. "By repealing the noninterference clause of the Medicare Act, the Senate is taking a dangerous step toward adopting price controls on prescription medicines," said Ken Johnson, PhRMA's senior vice president.

With a split of nine Republicans to four Democrats, proponents do not have the votes to ensure the direct negotiation language is ruled germane. This is "not the issue [Republicans] want to talk about. Period," the source said, adding "I just don't see them allowing that on the floor." (http://www.fdanews.com/did)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • 483sonline-logo-430x250

    483sOnline.com Your Personal Pre-inspection Toolkit

  • Globalmarketimage

    International Devices and Diagnostics Monitor

  • Cryolife_logo

    CryoLife’s Thoracoabdominal Stent Graft Receives CE Mark

  • Patentstablabel

    House Judiciary Committee Advances Patent Abuse Legislation

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing